Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senaparib plus bevacizumab maintenance in newly diagnosed BRCA wild-type advanced ovarian cancer
ChiCTR2500114463Phase 4Recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of senaparib and bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoint: 1-year progression-free survival rate. Started Dec 2025; status: recruiting.
02
Drugs
senaparibbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2500114463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114463.